Is cholesterol lowering with statins the gold standard for treating patients with cardiovascular risk and disease?
D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D003043:Cocarcinogenesis; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors; D009369:Neoplasms / Q000139:chemically induced*; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000187:drug effects
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D018836:Inflammation Mediators; D014409:Tumor Necrosis Factor-alpha